KAER Biotherapeutics
October 18, 2023
Franciscan D
Respiratory
Company Description: Donovan B. Yeates, Ph.D., Founder and CEO, KAER Biotherapeutics Corporation is introducing a two new game-changing product line, AeroPulsR. This device enables aqueous liquid surfactant suspensions to be delivered as liquid aerosols at high concentrations to treat respiratory distress in pediatric and adult patients. Dr. Yeates was CEO of the incubator company, BioTechPlex Corporation. He was a Senior Research Career Scientist in the Department of Veterans Affairs and a Professor in the Departments of Bioengineering and Medicine at the University of Illinois at Chicago. He was a Section Chief in the Department of Medicine and Director of a university wide Occupation Health and Safety Center. Dr. Yeates is an emeritus professor with over 90 publications and 25 patents. He is a past president of the Chicago Thoracic Society and served on the board of directors of the Illinois Biotechnology Organization (IBIO). He has a Ph.D. in Medical Biophysics from the University of Toronto.
State
California
Country
United States
Website
http://www.kaerbio.com
CEO/Top Company Official
Donovan Yeates, Ph.D.
Lead Product in Development
AeroPulsR, a new game-changing product that enables aqueous liquid surfactant suspensions as well as other small and large molecules with viscosities up to 50 cP to be delivered as liquid aerosols at high concentrations to treat pediatric and adult patients.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
SUPRAER Model3, SUPRAER-Clinic, AeroPulsR
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)